Clinical Trials Directory

Trials / Not Yet Recruiting

Not Yet RecruitingNCT07441200

Clinical Trial of NS-863 in Participants With Pulmonary Arterial Hypertension (PAH)

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Finding Trial to Evaluate the Efficacy and Safety of Orally Administered NS-863 in Participants With Pulmonary Arterial Hypertension (PAH)

Status
Not Yet Recruiting
Phase
Phase 2
Study type
Interventional
Enrollment
135 (estimated)
Sponsor
NS Pharma, Inc. · Industry
Sex
All
Age
18 Years – 75 Years
Healthy volunteers
Not accepted

Summary

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Finding Trial to Evaluate the Efficacy and Safety of Orally Administered NS-863 in Participants with Pulmonary Arterial Hypertension (PAH)

Conditions

Interventions

TypeNameDescription
DRUGNS-863 Low DoseNS-863 is an orally administered drug
DRUGNS-863 High DoseNS-863 is an orally administered drug
DRUGNS-863 PlaceboAn orally administered NS-863 matching placebo

Timeline

Start date
2026-07-01
Primary completion
2028-08-01
Completion
2028-11-01
First posted
2026-02-27
Last updated
2026-02-27

Regulatory

Source: ClinicalTrials.gov record NCT07441200. Inclusion in this directory is not an endorsement.

Clinical Trial of NS-863 in Participants With Pulmonary Arterial Hypertension (PAH) (NCT07441200) · Clinical Trials Directory